Correction to Protein Lysine Acetylation by p300/CBP.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Recent advances of dual PROTACs for potential therapeutic applications.Molecular diversity · 2026
   Review
2. Targeting lysine acetylation readers and writers.Nature reviews. Drug discovery · 2025
   Review
3. p300 nucleocytoplasmic shuttling underlies mTORC1 hyperactivation in Hutchinson-Gilford progeria syndrome.Nature cell biology · 2024
   Article
4. Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020
   Review
5. A Novel E2F1-EP300-VMP1 Pathway Mediates Gemcitabine-Induced Autophagy in Pancreatic Cancer Cells Carrying Oncogenic KRAS.Frontiers in endocrinology · 2020
   Article

Corrections and comments

• Erratum for
  Protein lysine acetylation by p300/CBP.2015

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.